Table 2

 Efficacy of hepatitis C treatment with pegylated interferon (PEG-IFN) plus ribavirin

StudyTreatmentHCV genotypeDuration (weeks)SVR (%)
Sustained virological response rates (SVR) depend on hepatitis C virus (HCV) genotype, dose, and duration of treatment.
TW4, four weeks of therapy.
Manns161.5 μg/kg PEG-IFN alpha-2bHCV-14842
800 mg ribavirinHCV-2/34882
1.5 μg/kg PEG-IFN alpha-2bHCV-14848 (retrospective)
>10.6 mg/kg ribavirinHCV-2/34888 (retrospective)
Fried19180 μg PEG-IFN alpha-2aHCV-14846
1000/1200 mg ribavirinHCV-2/34876
Hadziyannis20180 μg PEG-IFN alpha-2aHCV-12429
800 mg ribavirin4840
180 μg PEG-IFN alpha-2aHCV-12441
1000/1200 mg ribavirin4851
Zeuzem241.5 μg/kg PEG-IFN alpha-2bHCV-22493
800–1400 mg ribavirinHCV-379
Kamal1091.5 μg/kg PEG-IFN alpha-2bHCV-42429
1000/1200 mg ribavirin3666
von Wagner27180 μg PEG-IFN alpha-2aHCV-2/32436 if TW4 HCV-RNA ⩾600 IU/ml
800–1200 mg ribavirin2480 if TW4 HCV-RNA <600 IU/ml
1682 if TW4 HCV-RNA <600 IU/ml
Zeuzem321.5 μg/kg PEG-IFN alpha-2bHCV-1 LVL2450
800–1400 mg ribavirin(<600 000 IU/ml)89 if TW4 HCV-RNA negative (<29 IU/ml)